Latest News

In case you missed it, this week we had news on phase 3 data of envudeucitinib for psoriasis, a combination treatment of ixekizumab and tirzepatide for PsA, a BLA pathway for sonelokimab in HS, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Discover how trifarotene could enhance acne treatment in Malaysia, addressing both facial and truncal acne while improving hyperpigmentation and scarring.

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

A new study evaluates the quality and reliability of melasma posts on TikTok and Bilibili, highlighting gaps in treatment information and educational value.

Research reveals that structural changes in neoantigens enhance tumor rejection, offering new insights for personalized cancer immunotherapies.

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate-to-severe atopic dermatitis.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Explore the effectiveness of herbal acne therapies versus social media trends, revealing both promising treatments and potential misinformation risks.